Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

By Jürgen Braun, J. Brandt, J. Listing, A. Zink, R. Alten, W. Golder, E. Gromnica-lhle, H. Kellner, A. Krause, Matthias Schneider and 4 more. The Lancet, 2002

1,315 citations recorded by the source corpus.

Subfields: Epidemiology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/4fbbe1425343c58791ed6cb3f7f9d5f213ac19d1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Bradley

Citations in the corpus

• TNF‐mediated inflammatory disease (2008, background): “Infliximab is also an effective agent in patients with active ankylosing spondylitis, for inducing and maintaining remission and readministration to treat relapse after discontinuation of long-term therapy [115,116].”